Drug Trial Radar · NCT07827573
A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Nov 30, 2028
Study completion Nov 30, 2032
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate treatment adherence, tolerability, and patient-reported outcomes of participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (eBC) who are treated with giredestrant. The study will have two cohorts. Cohort A will comprise a broad upfront patient population with low-, medium-, or high-risk eBC. Cohort B will comprise patients with medium- or high-risk eBC who have completed adjuvant treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) (abemaciclib or ribociclib) and endocrine therapy and who are now switching to giredestrant monotherapy.
Conditions
- Early Breast Cancer
- Estrogen Receptor-Positive Breast Cancer
- HER2-Negative Breast Cancer
Interventions
GiredestrantDrug
Participants will receive giredestrant 30 mg orally once a day for up to 5 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Participants who Have Discontinued Giredestrant for any ReasonTime frame: Month 12
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Hematology Oncology Salem
Salem, Oregon · Recruiting
Virginia Cancer Institute
Richmond, Virginia · Recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
CHU de Québec - Hôpital du Saint-Sacrement
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.